argenx SE (argenx SE) Total Liabilities : $445 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is argenx SE Total Liabilities?

argenx SE's Total Liabilities for the quarter that ended in Dec. 2023 was $445 Mil.

argenx SE's quarterly Total Liabilities declined from Jun. 2023 ($335.74 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($444.95 Mil).

argenx SE's annual Total Liabilities increased from Dec. 2021 ($316.05 Mil) to Dec. 2022 ($320.56 Mil) and increased from Dec. 2022 ($320.56 Mil) to Dec. 2023 ($444.95 Mil).

argenx SE Total Liabilities Historical Data

The historical data trend for argenx SE's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

argenx SE Total Liabilities Chart

argenx SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

429.81

605.36

316.05

320.56

444.95

argenx SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															320.56	-	335.74	-	444.95

argenx SE Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

argenx SE's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	422.993	+	(15.354	+	2.7311486405779E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.155	+	1.449)
	=	445

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4542.458	-	4097.507
	=	445

argenx SE's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	422.993	+	(15.354	+	2.7311486405779E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	5.155	+	1.449)
	=	445

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	4542.458	-	4097.507
	=	445

argenx SE Total Liabilities Related Terms

Thank you for viewing the detailed overview of argenx SE's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

argenx SE (argenx SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (NAS:ARGX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ARGX:Mexico ARGXb:UK 0QW0:UK 1AEA:Germany 1AE:Germany 1AE:Germany A1RG34:Brazil ARGX:Belgium ARGX:Austria

Address

Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB

Website

https://www.argenx.com

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.